enGene Holdings Inc. (NASDAQ:ENGN) Short Interest Update

enGene Holdings Inc. (NASDAQ:ENGN - Get Free Report) experienced a notable decrease in short interest during February. As of February 28th, the total short interest was 60,300 shares, reflecting a decline of 31.9% from the previous total of 88,500 shares recorded on February 13th. Currently, only 0.3% of the company’s shares are sold short. With an average daily trading volume of 131,100 shares, the days-to-cover ratio is now at 0.5 days.

enGene Stock Performance

On Friday, shares of NASDAQ ENGN opened at $5.40. The stock has fluctuated between a one-year low of $4.42 and a one-year high of $18.40. enGene maintains a debt-to-equity ratio of 0.08, with both a current and quick ratio of 16.87. The 50-day simple moving average stands at $6.51, while the two-hundred-day moving average is $7.11. The company boasts a market capitalization of $275.28 million, a P/E ratio of -9.31, and a beta of -0.61.

enGene last reported its quarterly earnings on December 19th, revealing an earnings per share (EPS) of ($0.34), which exceeded analysts' predictions of ($0.40) by $0.06. Looking ahead, analysts collectively foresee that enGene will report an EPS of -1.56 for the current fiscal year.

Analysts and Price Targets

Several research analysts have recently provided updates on enGene shares. Piper Sandler initiated coverage with an "overweight" rating and assigned a price target of $26.00 on February 18th. In contrast, UBS Group downgraded the stock from a "buy" rating to a "neutral" rating, while adjusting the price target from $34.00 to $7.00 on February 14th. Raymond James also began coverage on November 27th, offering an "outperform" rating with a target price of $23.00. JMP Securities reaffirmed an "outperform" rating with an $18.00 target on December 23rd. Furthermore, Citizens JMP raised its rating to a "strong-buy" on November 18th. Currently, one analyst has assigned a hold rating, eight have offered buy ratings, and one has given a strong buy rating to the stock. According to MarketBeat, the consensus rating for enGene is "Buy" with an average price target of $25.22.

Institutional Investors' Movements

In recent times, various institutional investors and hedge funds have adjusted their stakes in enGene. Fcpm Iii Services B.V. increased its position by 11.0% in the fourth quarter, now owning 9,632,561 shares valued at $64,057,000 after acquiring an additional 954,610 shares. VR Adviser LLC raised its holdings by 41.5%, acquiring 1,480,573 shares during the same quarter to reach a total of 5,046,414 shares worth $33,559,000. Deep Track Capital LP significantly upped its holdings by 74.8%, bringing its total to 4,557,575 shares valued at $30,308,000 after purchasing an additional 1,949,942 shares. Blue Owl Capital Holdings LP also increased its shares by 3.3%, now holding 3,159,975 shares worth $21,014,000. Lastly, Point72 Asset Management L.P. raised its stake by 84.7%, acquiring 561,797 additional shares to reach a total of 1,224,797. Overall, 64.16% of enGene's stock is currently owned by institutional investors.

About enGene Holdings Inc.

enGene Holdings Inc. operates through its subsidiary, enGene, Inc., as a clinical-stage biotechnology firm focusing on developing genetic medicines. The company specializes in delivering therapeutics to mucosal tissues and various organs. Its primary product candidate is EG-70 (detalimogene voraplasmid), which serves as a non-viral immunotherapy intended for patients with non-muscle invasive bladder cancer who are unresponsive to Bacillus Calmette-Guérin treatment.

short, interest, stocks